Are GLP-1s Doing More Than Shrinking Waistlines in PsA? Save

We have spent years telling patients with psoriatic arthritis (PsA) that weight loss may improve symptoms and reduce cardiometabolic risk. A new ACR Convergence 2026 abstract asks the more provocative question: could GLP-1–based therapy influence PsA outcomes even after accounting for the change on the scale?

In abstract #0373, Pankti Mehta and colleagues examined patients from a longitudinal PsA cohort who initiated GLP-1 receptor agonist or dual GIP/GLP-1 therapy and compared them with matched controls. Baseline body mass index was similar, approximately 35 kg/m² in both groups. Diabetes was much more common in those receiving incretin therapy.

At 12 months, 44.4% of treated patients with available assessments had lost more than 5% of baseline weight, versus 12.8% of controls. In adjusted models, medication exposure was associated with modest reductions in clinical Disease Activity Index for Psoriatic Arthritis (cDAPSA), DAPSA and patient-reported pain. Associations persisted after additional adjustment for BMI change. For cDAPSA, the estimated association was beta −0.43 per month of treatment after accounting for BMI change.

A key caveat: investigators found no significant associations with CRP, swollen- or tender-joint counts, or PASI. These findings suggest possible benefits independent of weight loss but do not establish that GLP-1 drugs directly reduce objective joint or skin inflammation.

There are other uncertainties. 

This is not a randomized trial, available 12-month assessments were limited, and metabolic treatment may influence pain perception, function or health behaviors in ways difficult to fully disentangle. Statistical adjustment for BMI change is not the same as a mechanistic experiment proving an anti-inflammatory effect.

How should rheumatologists apply these findings in practice? 

First, recognize that obesity treatment may improve dimensions of health that matter enormously to patients. Second, do not interpret better pain scores alone as permission to withdraw a successful disease-modifying regimen. We should continue to examine swollen joints, entheses, skin and inflammatory markers—and use imaging selectively when the clinical picture is unclear.

The exciting possibility is that metabolic and immunologic care will increasingly intersect. For now, these findings do not establish GLP-1s as PsA treatments, but they provide a strong rationale for prospective studies assessing both patient-centered outcomes and objective measures of inflammation.